Table 1. Patient demographics.
| Parameter | Entire cohort (N=710, %) | Evaluation cohort (N=228, %) | Validation cohort (N=482, %) | P value |
|---|---|---|---|---|
| Gender | 0.585 | |||
| Male | 435 (61.3) | 143 (62.7) | 292 (60.6) | |
| Female | 275 (38.7) | 85 (37.3) | 190 (39.4) | |
| Age, median (range), years | 63 (22.0–89.0) | 62 (28.0–83.0) | 63 (22.0–89.0) | 0.977 |
| Hepatic resection | <0.001 | |||
| Minor (<3 segments) | 362 (51.0) | 151 (66.2) | 211 (43.8) | |
| Major (≥3 segments) | 348 (49.0) | 77 (33.8) | 271 (56.2) | |
| Tumor type | <0.001 | |||
| mCRC | 491 (69.2) | 228 (100.0) | 263 (54.6) | |
| HCC | 76 (10.7) | 0 (0.0) | 76 (15.8) | |
| CCC | 100 (14.1) | 0 (0.0) | 100 (20.7) | |
| Benign | 16 (2.3) | 0 (0.0) | 16 (3.3) | |
| Other | 27 (3.8) | 0 (0.0) | 27 (5.6) | |
| Preoperative parameters, median (range) | ||||
| PDR (%) | 20.0 (3.5–43.0) | 19.0 (3.5–35.8) | 22.0 (8.0–43.0) | <0.001 |
| R15 (%) | 5.0 (0.2–59.2) | 6.0 (0.5–59.2) | 3.7 (0.2–32.0) | <0.001 |
| Platelets (×103/µL) | 198 (43.0–679.0) | 139 (49.0–503.0) | 221 (43.0–679.0) | <0.001 |
| SB (mg/dL) | 0.61 (0.15–18.50) | 0.63 (0.24–2.26) | 0.60 (0.15–18.50) | 0.026 |
| PT (%) | 104 (39.0–150.0) | 107 (45.0–147.0) | 102 (39.0-150.0) | 0.002 |
| AP (U/L) | 99 (14.0–2,005.0) | 108 (42.0–1,111.0) | 95 (14.0-2005.0) | 0.035 |
| GGT (U/L) | 58 (0.0–2,055.0) | 47 (9.0–968.0) | 63 (0.0–2,055.0) | <0.001 |
| AST (U/L) | 29 (5.0–615.0) | 28 (5.0–496.0) | 30 (12.0–615.0) | 0.001 |
| ALT (U/L) | 26 (2.0–497.0) | 22 (2.0–410.0) | 28 (4.0–497.0) | <0.001 |
| Albumin (g/L) | 42.0 (21.0–52.0) | 41.0 (21.0–50.0) | 43.0 (25.5–52.0) | <0.001 |
| ATIII-activity (%) | 105 (51.0–168.0) | 107 (67.0–168.0) | 103 (51.0–136.0) | 0.003 |
| CRP (mg/dL) | 0.40 (0.02–33.58) | 0.5 (0.04–9.67) | 0.32 (0.02–33.58) | 0.004 |
| Postoperative outcome | ||||
| Liver dysfunction (ISGLS) | 67 (9.4) | 26 (11.4) | 41 (8.5) | 0.218 |
| Liver dysfunction (Peak7) | 36 (5.1) | 6 (2.6) | 30 (6.2) | 0.042 |
| Liver dysfunction (50-50) | 18 (2.5) | 6 (2.6) | 12 (2.5) | 0.911 |
| Morbidity (Dindo et al.) | 284 (40.0) | 81 (35.5) | 203 (42.1) | 0.094 |
| ICU stay, median (range), days | 1 (0.0–42.0) | 1 (0.0–42.0) | 1 (0.0–26.0) | <0.001 |
| Total hospitalization, median (range), days | 10 (3.0–117.0) | 9 (4.0–77.0) | 10 (3.0–117.0) | 0.002 |
| Postoperative mortality | 17 (2.4) | 7 (3.1) | 10 (2.1) | 0.418 |
mCRC, metastasized colorectal carcinoma; HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; PDR, plasma disappearance rate; R15, retention rate at 15 minutes; SB, serum bilirubin; PT, prothrombin time; AP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ATIII, antithrombinIII-activity; CRP, C-reactive protein; ISGLS, international study group on liver surgery; ICU, intensive care unit.